|
Delayed
NSE India S.E.
02:41:39 25/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,952.10 INR | -2.25% |
|
-2.81% | +37.66% |
| 14/08 | Ipca Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 | |
| 13/08 | Ipca Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Ipca Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,70,385 | 2,05,589 | 3,13,934 | 3,81,038 | 4,06,231 | 5,06,673 | - | - |
| Change | - | -23.96% | 52.7% | 21.38% | 6.61% | 24.73% | - | - |
| Enterprise Value (EV) 1 | 2,75,070 | 2,01,870 | 3,25,349 | 3,91,231 | 4,08,673 | 4,96,023 | 4,86,716 | 4,74,529 |
| Change | - | -26.61% | 61.17% | 20.25% | 4.46% | 21.37% | -1.88% | -2.5% |
| P/E | 30.6x | 43.6x | 57.4x | 51.6x | 35.6x | 33.4x | 28.6x | 24.9x |
| PBR | 4.92x | 2.58x | 4.96x | 5.48x | 5.04x | 5.32x | 4.58x | 3.91x |
| PEG | - | -0.9x | 3.6x | 1.5x | 0.7x | 1x | 1.7x | 1.7x |
| Capitalization / Revenue | 4.64x | 3.29x | 4.07x | 4.26x | 4.21x | 4.61x | 4.13x | 3.73x |
| EV / Revenue | 4.72x | 3.23x | 4.22x | 4.38x | 4.24x | 4.51x | 3.97x | 3.49x |
| EV / EBITDA | 21x | 21.8x | 24.6x | 22.7x | 20.7x | 19.6x | 16.7x | 14.3x |
| EV / EBIT | 25.6x | 30.3x | 33.8x | 29.5x | 26.2x | 24.1x | 20.6x | 17.5x |
| EV / FCF | 72.9x | 64.8x | 60.9x | 71.7x | 83.5x | 63.4x | 40.3x | 30.2x |
| FCF Yield | 1.37% | 1.54% | 1.64% | 1.4% | 1.2% | 1.58% | 2.48% | 3.31% |
| Dividend per Share 2 | 8 | 4 | 4 | 2 | 6 | 5.769 | 6.185 | 7.114 |
| Rate of return | 0.75% | 0.49% | 0.32% | 0.13% | 0.37% | 0.29% | 0.31% | 0.36% |
| EPS 2 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 | 59.87 | 69.92 | 80.13 |
| Distribution rate | 23% | 21.5% | 18.5% | 6.88% | 13.3% | 9.64% | 8.84% | 8.88% |
| Net sales 1 | 58,298 | 62,443 | 77,050 | 89,396 | 96,463 | 1,09,955 | 1,22,660 | 1,36,008 |
| EBITDA 1 | 13,073 | 9,268 | 13,212 | 17,261 | 19,786 | 25,244 | 29,171 | 33,139 |
| EBIT 1 | 10,748 | 6,652 | 9,639 | 13,283 | 15,604 | 20,577 | 23,583 | 27,169 |
| Net income 1 | 8,841 | 4,713 | 5,474 | 7,377 | 11,411 | 15,145 | 17,797 | 20,425 |
| Net Debt 1 | 4,685 | -3,720 | 11,415 | 10,193 | 2,442 | -10,650 | -19,956 | -32,144 |
| Reference price 2 | 1,065.75 | 810.35 | 1,237.40 | 1,501.90 | 1,601.20 | 1,997.10 | 1,997.10 | 1,997.10 |
| Nbr of stocks (in thousands) | 2,53,704 | 2,53,704 | 2,53,704 | 2,53,704 | 2,53,704 | 2,53,704 | - | - |
| Announcement Date | 24/05/22 | 29/05/23 | 29/05/24 | 29/05/25 | 29/05/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.36x | 4.51x | 19.65x | 0.29% | 527.83Cr | |
| 33.6x | 12.18x | 24.75x | 0.59% | 1,05300Cr | |
| 30.11x | 6.7x | 18.74x | 1.98% | 65TCr | |
| 33.53x | 7.84x | 16.21x | 2.59% | 47TCr | |
| 19.76x | 4.82x | 11.93x | 2.75% | 35TCr | |
| 20.25x | 5.27x | 13.08x | 3.03% | 27TCr | |
| 20.9x | 4.34x | 12.34x | 2.04% | 25TCr | |
| 25.65x | 6.7x | 11.94x | 2.48% | 22TCr | |
| -45.27x | 6.59x | 25.75x | 2.2% | 19TCr | |
| 11.33x | 4.13x | 8.58x | 4.44% | 17TCr | |
| Average | 18.32x | 6.31x | 16.30x | 2.24% | 36.33TCr | |
| Weighted average by Cap. | 24.18x | 7.85x | 18.10x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IPCALAB Stock
- Valuation Ipca Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
